Highlights

  • Noxopharm shares surged 40.00% to AUD 0.084 on 26 May 2026, following the release of new data linked to its Sofra technology platform and cancer immunotherapy program.
  • Proprietary oligonucleotides reportedly amplified TLR8 activity by more than 200-fold in human skin biopsy studies.
  • Animal model testing showed almost three-fold improvement in TLR8 activity.
  • The company is advancing a Drug Development program targeting Toll-like receptor 8 (TLR8) in cancer treatment.
  • The global immuno-oncology market is projected to grow significantly over the coming decade.

Noxopharm Ltd (ASX:NOX) shares surged 40.00% to AUD 0.084 during the morning session on 26 May 2026 after the clinical-stage biotechnology company released new data supporting the cancer-fighting potential of its Sofra technology platform.

The sharp share price move followed the company’s announcement detailing experimental results involving immune activation and Toll-like receptor 8 (TLR8), an emerging target in immuno-oncology research.

Despite today’s strong rally, the stock remains approximately 20% higher over the past year.

Investor attention appeared to focus on the company’s claims that its proprietary oligonucleotides significantly amplified immune system activity in both human and animal studies, potentially opening new opportunities in cancer treatment development.

New Data Highlights TLR8 Immune Activation Potential

Noxopharm stated that its Sofra technology platform is being advanced as part of a cancer-focused immuno-oncology program aimed at harnessing the body’s immune system to attack cancer cells.

The company explained that Toll-like receptors are critical immune system sensors involved in detecting threats and activating immune responses.

Among these receptors, TLR8 has become an area of increasing interest within cancer research due to its role in stimulating anti-cancer immune activity.

According to Noxopharm, the company has developed proprietary oligonucleotides capable of substantially amplifying TLR8 activity compared to existing drugs currently in clinical development.

The company believes this approach could potentially improve the effectiveness of conventional cancer treatments such as chemotherapy and radiotherapy when used in combination.

Management described the strategy as a more targeted and controllable way of activating the immune system against cancer.

Human and Animal Studies Delivered Encouraging Results

The announcement included data from both ex vivo human tissue studies and in vivo animal model experiments.

In one human skin biopsy model, Noxopharm reported that a proprietary TLR8-amplifying oligonucleotide increased immune activation levels by more than 200-fold when combined with a clinical-stage TLR8 agonist.

The study involved culturing human skin biopsies ex vivo and measuring immune activation biomarkers after treatment.

The company stated that the immune response generated by the combination significantly exceeded that produced by the agonist alone.

In a separate transgenic mouse model expressing human TLR8 receptors, Noxopharm reported that its oligonucleotide increased TLR8-driven immune activity by almost three-fold.

The company assessed immune responses in the spleen using gene expression analysis of several TLR8-responsive biomarkers.

Management noted that these experiments represented an important step in validating the activity of the technology across both human and animal systems.

Sofra Platform Built Around Immune System Discovery

Noxopharm’s Sofra platform is based on short nucleic acid sequences known as oligonucleotides, which are designed to regulate immune system activity.

The company explained that these molecules act on specific immune sensors to either stimulate or reduce inflammatory responses depending on the disease target.

Sofra was developed from what the company described as a breakthrough discovery involving the regulation of innate immune receptors.

The platform has applications spanning several disease areas, including:

  • cancer
  • autoimmune disorders
  • inflammatory diseases
  • RNA therapeutics
  • Vaccine enhancement

Noxopharm stated that its TLR8-focused immuno-oncology program is protected by a granted United States Patent.

The company believes its understanding of how TLR8 receptors are naturally regulated provides a differentiated approach within the immuno-oncology sector.

Cancer Immunotherapy Remains a Rapidly Expanding Market

The broader immuno-oncology sector has become one of the largest and fastest-growing segments within global biotechnology and pharmaceutical markets.

According to figures cited by Noxopharm, the immuno-oncology market is expected to expand from approximately US$35 billion in 2025 to US$185 billion by 2035.

The company also referenced separate estimates suggesting the worldwide immuno-oncology market could reach US$284 billion by 2033.

Despite the growth of immunotherapy over recent years, management noted that many patients still experience limited treatment responses, creating Demand for alternative approaches.

Noxopharm believes its TLR8 amplification strategy could contribute to overcoming some of these limitations by improving immune activation against cancer cells.

Independent Scientific Commentary Adds Credibility

The company’s announcement included commentary from Professor Seija Lehnardt of Charité – Universitätsmedizin Berlin, a researcher with expertise in TLR7 and TLR8 biology.

Professor Lehnardt stated that the short oligonucleotides developed by Noxopharm demonstrated potential to significantly enhance the therapeutic effectiveness of TLR8 sensing in both laboratory and animal studies.

The inclusion of external scientific commentary appeared to reinforce the credibility of the underlying research and the significance of the findings.

Company Preparing Further Testing

Following the latest data, Noxopharm confirmed that it is now expanding testing activities involving its TLR8-potentiating oligonucleotides.

The company stated that upcoming work will include:

  • testing in humanised TLR8 mice
  • evaluation across various cancer models
  • further validation of the technology platform

Management indicated that these studies are expected to take place over the coming months.

The company appears focused on strengthening the preclinical evidence base before advancing toward broader development opportunities.

Oncology and Inflammation Remain Core Focus Areas

Noxopharm is a clinical-stage Australian biotechnology company focused on treatments for cancer and inflammation.

The company operates through two technology platforms:

  • Sofra
  • Chroma

Sofra is being developed across inflammation, autoimmune disease, oncology, and mRNA medicine enhancement applications.

Meanwhile, the Chroma platform is focused specifically on oncology.

Noxopharm also highlighted the potential role of Sofra in improving the safety profile of mRNA medicines and vaccines.

Beyond cancer, the company sees opportunities in autoimmune diseases such as rheumatoid arthritis, lupus, and diabetes.

According to figures referenced in the announcement, the global autoimmune disease therapeutics market was valued at US$163.2 billion in 2024 and could grow to US$219.6 billion by 2035.

Market Reaction Reflects Investor Interest in Oncology Pipeline

Today’s substantial share price increase suggests investors responded favourably to the latest Sofra platform data and the company’s positioning within the growing immuno-oncology sector.

The reported 200-fold amplification of immune activation in human biopsy studies appeared to be one of the key figures attracting market attention.

The update also reinforced Noxopharm’s strategy of developing differentiated immune-modulating technologies targeting unmet needs in cancer treatment.

At the same time, the company remains in the clinical-stage biotechnology category, meaning future progress will depend on ongoing preclinical validation, clinical trial development, regulatory pathways, and commercial execution.

Nevertheless, the latest announcement represents another operational milestone as Noxopharm continues advancing its oncology-focused technology programs.